Clinical outcomes and prognostic factors in patients with breast diffuse large B cell lymphoma; Consortium for Improving Survival of Lymphoma (CISL) study

BMC Cancer

Volumn 10, Issue , 2010, Pages

  Yhim, Ho Young ^a   Kang, Hye J ^b   Choi, Yoon H ^b   Kim, Seok J ^c   Kim, Won S ^c   Chae, Yee S ^d   Kim, Jin S ^e   Choi, Chul W ^f   Oh, Sung Y ^g   Eom, Hyeon S ^h   Kim, Jeong A ⁱ   Lee, Jae H ^j   Won, Jong Ho ^k   Shim, Hyeok ^l   Lee, Je Jung ^m   Sung, Hwa J ⁿ   Kim, Hyo J ^o   Lee, Dae H ^p   Suh, Cheolwon ^p   Kwak, Jae Yong ^a  

^a Chonbuk National University Medical School   (South Korea)

^b Korea Cancer Center Hospital   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Kyungpook National University School of Medicine   (South Korea)

^e Yonsei University College of Medicine   (South Korea)

^f Korea University College of Medicine   (South Korea)

^g Dong A University College of Medicine   (South Korea)

^h National Cancer Center   (South Korea)

ⁱ The Catholic University of Korea College of Medicine   (South Korea)

^j Gachon University   (South Korea)

^k Soonchunhyang University College of Medicine   (South Korea)

^l Wonkwang University School of Medicine   (South Korea)

^m Chonnam National University Medical School   (South Korea)

ⁿ Korea University Ansan Hospital   (South Korea)

^o Hallym University College of Medicine   (South Korea)

^p University of Ulsan College of Medicine   (South Korea)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ANTINEOPLASTIC AGENT; RITUXIMAB;

ADULT; AGED; ARTICLE; B CELL LYMPHOMA; BREAST METASTASIS; BREAST SURGERY; CANCER RADIOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM METASTASIS; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; FOLLOW UP; HEALTH CARE FACILITY; HUMAN; INCIDENCE; KOREA; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PROGNOSIS; TREATMENT OUTCOME; BREAST TUMOR; CANCER STAGING; CHI SQUARE DISTRIBUTION; CLASSIFICATION; CLINICAL TRIAL; DISEASE COURSE; KAPLAN MEIER METHOD; LARGE CELL LYMPHOMA; MIDDLE AGED; MORTALITY; MULTICENTER STUDY; PATHOLOGY; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SOUTH KOREA; TIME;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; CHI-SQUARE DISTRIBUTION; DISEASE PROGRESSION; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; KAPLAN-MEIERS ESTIMATE; LYMPHOMA, LARGE B-CELL, DIFFUSE; MIDDLE AGED; NEOPLASM STAGING; PROPORTIONAL HAZARDS MODELS; REPUBLIC OF KOREA; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 77953679537     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-10-321     Document Type: Article

References (29)

1. Zucca E. Extranodal lymphoma: a reappraisal. Ann Oncol 2008, 19(Suppl 4):iv77-80. 10.1093/annonc/mdn204, 18519412.
2. Dawson IM, Cornes JS, Morson BC. Primary malignant lymphoid tumours of the intestinal tract. Report of 37 cases with a study of factors influencing prognosis. Br J Surg 1961, 49:80-89. 10.1002/bjs.18004921319, 13884035.
3. Lewin KJ, Ranchod M, Dorfman RF. Lymphomas of the gastrointestinal tract: a study of 117 cases presenting with gastrointestinal disease. Cancer 1978, 42(2):693-707. 10.1002/1097-0142(197808)42:2<693::AID-CNCR2820420241>3.0.CO;2-J, 354774.
4. Krol AD, le Cessie S, Snijder S, Kluin-Nelemans JC, Kluin PM, Noordijk EM. Primary extranodal non-Hodgkin's lymphoma (NHL): the impact of alternative definitions tested in the Comprehensive Cancer Centre West population-based NHL registry. Ann Oncol 2003, 14(1):131-139. 10.1093/annonc/mdg004, 12488305.
5. Herrmann R, Panahon AM, Barcos MP, Walsh D, Stutzman L. Gastrointestinal involvement in non-Hodgkin's lymphoma. Cancer 1980, 46(1):215-222. 10.1002/1097-0142(19800701)46:1<215::AID-CNCR2820460136>3.0.CO;2-6, 7388763.
6. Gospodarowicz MK, Ferry JA, Cavalli F. Unique aspects of primary extranodal lymphomas. Non-Hodgkin's Lymphomas 2003, 685-707. Philadelphia, PA: Lippincott Williams & Wilkins, Mauch PM, Armitago JO, Harris NL.
7. Wiseman C, Liao KT. Primary lymphoma of the breast. Cancer 1972, 29(6):1705-1712. 10.1002/1097-0142(197206)29:6<1705::AID-CNCR2820290640>3.0.CO;2-I, 4555557.
8. Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM, Lister TA, Vose J, Grillo-Lopez A, Hagenbeek A, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999, 17(4):1244-1253.
9. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data 1980, New York: John Wiley and Sons.
10. Gholam D, Bibeau F, El Weshi A, Bosq J, Ribrag V. Primary breast lymphoma. Leuk Lymphoma 2003, 44(7):1173-1178. 10.1080/1042819031000079195, 12916870.
11. Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C, Christian B, Lepage E, Tilly H, Morschhauser F, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 2005, 23(18):4117-4126. 10.1200/JCO.2005.09.131, 15867204.
12. Ryan G, Martinelli G, Kuper-Hommel M, Tsang R, Pruneri G, Yuen K, Roos D, Lennard A, Devizzi L, Crabb S, et al. Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group. Ann Oncol 2008, 19(2):233-241. 10.1093/annonc/mdm471, 17932394.
13. Aviles A, Delgado S, Nambo MJ, Neri N, Murillo E, Cleto S. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005, 69(3):256-260. 10.1159/000088333, 16166814.
14. Au WY, Chan AC, Chow LW, Liang R. Lymphoma of the breast in Hong Kong Chinese. Hematol Oncol 1997, 15(1):33-38. 10.1002/(SICI)1099-1069(199702)15:1<33::AID-HON595>3.0.CO;2-K, 9378471.
15. Ha CS, Dubey P, Goyal LK, Hess M, Cabanillas F, Cox JD. Localized primary non-Hodgkin lymphoma of the breast. Am J Clin Oncol 1998, 21(4):376-380. 10.1097/00000421-199808000-00012, 9708637.
16. Jennings WC, Baker RS, Murray SS, Howard CA, Parker DE, Peabody LF, Vice HM, Sheehan WW, Broughan TA. Primary breast lymphoma: the role of mastectomy and the importance of lymph node status. Ann Surg 2007, 245(5):784-789. 10.1097/01.sla.0000254418.90192.59, 1877073, 17457172.
17. Wong WW, Schild SE, Halyard MY, Schomberg PJ. Primary non-Hodgkin lymphoma of the breast: The Mayo Clinic Experience. J Surg Oncol 2002, 80(1):19-25. discussion 26, 10.1002/jso.10084, 11967901.
18. Zucca E, Conconi A, Mughal TI, Sarris AH, Seymour JF, Vitolo U, Klasa R, Ozsahin M, Mead GM, Gianni MA, et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003, 21(1):20-27. 10.1200/JCO.2003.11.141, 12506165.
19. Domchek SM, Hecht JL, Fleming MD, Pinkus GS, Canellos GP. Lymphomas of the breast: primary and secondary involvement. Cancer 2002, 94(1):6-13. 10.1002/cncr.10163, 11815954.
20. Miller TP, Dahlberg S, Cassady JR, Adelstein DJ, Spier CM, Grogan TM, LeBlanc M, Carlin S, Chase E, Fisher RI. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. N Engl J Med 1998, 339(1):21-26. 10.1056/NEJM199807023390104, 9647875.
21. Miller TP, LeBlanc M, Spier CM, Chase E, Fischer RJ. CHOP alone compared to CHOP plus radiotherapy for early stage aggressive non-Hodgkin's lymphomas: update of the Southwest Oncology Group (SWOG) Randomized Trial. Blood 2001, 98:742a-743a.
22. Coiffier B, Lepage E, Briere J, Herbrecht R, Tilly H, Bouabdallah R, Morel P, Van Den Neste E, Salles G, Gaulard P, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(4):235-242. 10.1056/NEJMoa011795, 11807147.
23. Pfreundschuh M, Trumper L, Osterborg A, Pettengell R, Trneny M, Imrie K, Ma D, Gill D, Walewski J, Zinzani PL, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006, 7(5):379-391. 10.1016/S1470-2045(06)70664-7, 16648042.
24. Persky DO, Unger JM, Spier CM, Stea B, LeBlanc M, McCarty MJ, Rimsza LM, Fisher RI, Miller TP. Phase II study of rituximab plus three cycles of CHOP and involved-field radiotherapy for patients with limited-stage aggressive B-cell lymphoma: Southwest Oncology Group study 0014. J Clin Oncol 2008, 26(14):2258-2263. 10.1200/JCO.2007.13.6929, 18413640.
25. Aviles A, Castaneda C, Neri N, Cleto S, Nambo MJ. Rituximab and dose dense chemotherapy in primary breast lymphoma. Haematologica 2007, 92(8):1147-1148. 10.3324/haematol.10892, 17650450.
26. Rosenwald A, Wright G, Chan WC, Connors JM, Campo E, Fisher RI, Gascoyne RD, Muller-Hermelink HK, Smeland EB, Giltnane JM, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346(25):1937-1947. 10.1056/NEJMoa012914, 12075054.
27. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 2004, 103(1):275-282. 10.1182/blood-2003-05-1545, 14504078.
28. Nyman H, Adde M, Karjalainen-Lindsberg ML, Taskinen M, Berglund M, Amini RM, Blomqvist C, Enblad G, Leppa S. Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. Blood 2007, 109(11):4930-4935. 10.1182/blood-2006-09-047068, 17299093.
29. Winter JN, Weller EA, Horning SJ, Krajewska M, Variakojis D, Habermann TM, Fisher RI, Kurtin PJ, Macon WR, Chhanabhai M, et al. Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. Blood 2006, 107(11):4207-4213. 10.1182/blood-2005-10-4222, 1895783, 16449523.